There's plenty of useful tasks for your server's GPU ...
Though it has some limitations.
Glioblastoma is the most aggressive primary brain cancer, with median survival under two years from diagnosis despite current standard-of-care interventions. The molecular target of TTX-MC138, ...
BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company with a market capitalization of just $7.91 million, and Quantum Leap Healthcare Collaborative announced Thursday a ...
Contributing Editor Jan Ozer recently spoke with Alex Davies, senior analyst at Rethink Technology Research, about Rethink’s new report, “The Media and Entertainment Transcoding Workload and Device ...
The MarketWatch News Department was not involved in the creation of this content. -- TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences -- Concurrent ...
TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...
(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage ...